(19)
(11) EP 3 575 326 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.05.2022 Bulletin 2022/21

(45) Mention of the grant of the patent:
13.04.2022 Bulletin 2022/15

(21) Application number: 19185175.7

(22) Date of filing: 17.12.2013
(51) International Patent Classification (IPC): 
C07K 19/00(2006.01)
A61K 38/45(2006.01)
C07K 14/705(2006.01)
C12N 15/62(2006.01)
 A61K 38/16(2006.01)
A61P 35/02(2006.01)
C07K 16/00(2006.01)
A61K 38/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2319/30; A61K 38/00; C07K 14/70503; A61P 35/00; A61P 35/02; A61P 43/00

(54)

TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS

BEHANDLUNG VON CD47+-KRANKHEITSZELLEN MIT SIRP-ALPHA-FC-FUSIONEN

TRAITEMENT DE CELLULES TUMORALES À CD47+ AVEC DES FUSIONS SIRP ALPHA/FC

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 17.12.2012 US 201261738008 P

(43) Date of publication of application:
04.12.2019 Bulletin 2019/49

(60) Divisional application:
22162692.2

(62) Application number of the earlier application in accordance with Art. 76 EPC:
13865442.1 / 2931752

(73) Proprietor: Trillium Therapeutics ULC
Mississauga, Ontario L5L 1J9 (CA)

(72) Inventors:
  • UGER, Robert Adam
    Richmond Hill, Ontario L4C 7S4 (CA)
  • SLAVOVA-PETROVA, Penka Slavtcheva
    Toronto, Ontario M8V 3X1 (CA)
  • PANG, Xinli
    Brampton, Ontario L6R 3H1 (CA)

(74) Representative: Script IP Limited 
Turnpike House 18 Bridge Street
Frome Somerset BA11 1BB
Frome Somerset BA11 1BB (GB)


(56) References cited: : 
WO-A1-2009/046541
 WO-A1-2010/130053
   
  • A. NEIL BARCLAY ET AL: ") and CD47: Structure, Function, and Therapeutic Target", ANNUAL REVIEW OF IMMUNOLOGY, vol. 32, no. 1, 21 March 2014 (2014-03-21) , pages 25-50, XP055166307, ISSN: 0732-0582, DOI: 10.1146/annurev-immunol-032713-120142
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).